EX-99.1 2 d842994dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement,

application for quotation of additional securities

and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

 

 Name of entity

Immutep Limited (IMM)

 

 

 ABN

 

90 009 237 889

 

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

 

    1    +Class of +securities issued or to be issued      

1. Unlisted Performance Rights

2. Unlisted Performance Rights

3. Ordinary Shares

4. Ordinary Shares

 

        
    2    Number of +securities issued or to be issued (if known) or maximum number which may be issued      

1. 3,600,000 Unlisted Performance Rights

2. 1,500,000 Unlisted Performance Rights

3. 833,334 Ordinary Shares

4. 250,000 Ordinary Shares

 


    3    Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)     

    1. Performance Rights

 

                 Number of performance rights    3,600,000 (on a post-consolidation basis)
     Vesting conditions   

Service-based vesting conditions only

 

     Tranche 1   

1,200,000 on 1 October 2020

 

   
        Tranche 2   

1,200,000 on 1 October 2021

 

   
        Tranche 3    1,200,000 on 1 October 2022
   
        Expiry Date   

The Performance Rights will expire, if not exercised, one year after the relevant vesting date for each tranche of performance rights (see above).

 

   
        Price of performance rights   

Performance Rights will be granted at no cost. Once the vesting condition is satisfied (or waived in exceptional circumstances), the Performance Rights will be exercisable at nil cost.

 

                

 

    2. Performance Rights

 

                 Number of performance rights    1,500,000 (on a post-consolidation basis)
   
        Vesting conditions   

The Performance Rights will vest in three equal tranches based on Mr Meyers continuing as a Director on the following dates

 

   
        Tranche 1   

500,000 (on a post-Consolidation basis) on 1 October 2021 (being for service from 1 October 2020 to 30 September 2021);

 

   
        Tranche 2   

500,000 (on a post-Consolidation basis) on 1 October 2022 (being for service from 1 October 2021 to 30 September 2022); and

 

   
        Tranche 3   

500,000 (on a post-Consolidation basis) on 1 October 2023 (being for service from 1 October 2022 to 30 September 2023).

 

   
        Expiry Date   

The Performance Rights will expire, if not exercised, one year after Vesting Date.

 

   
        Price of performance rights   

Performance Rights will be granted at no cost. Once the vesting conditions (service only) are met (or waived in exceptional circumstances), the Performance Rights will be exercisable at nil cost.

 

                     

    3. Pari passu with existing Fully Paid Ordinary Shares

    4. Pari passu with existing Fully Paid Ordinary Shares

 

+ See chapter 19 for defined terms.          
Appendix 3B Page 2       04/03/2013


    4   

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

 

If the additional +securities do not rank equally, please state:

 

•  the date from which they do

 

•  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

 

•  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

  

    

  

1.  Yes, if/when the Performance Rights vest to shares

2.  Yes, if/when the Performance Rights vest to shares

3.  ‘Pari Passu’ with existing Fully Paid Ordinary Shares

4.  ‘Pari Passu’ with existing Fully Paid Ordinary Shares

 

        
 
    5    Issue price or consideration      

1.  Nil

 

2.  Nil

 

3.  Nil

 

4.  Nil

 

        
 
    6   

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

     

1.  Issue to Chief Executive Officer under the Executive Incentive Plan

 

2.  Issue to Pete Meyers in lieu of cash for his services as a non-executive director, in accordance with shareholder approval at the AGM held on 1 November 2019.

 

3.  Vesting & exercise of Performance Rights under the Executive Incentive Plan into fully paid ordinary shares.

 

4.  Dr Russell Howard exercises 2nd tranche of his performance rights which vested to him i.e. 250,000 (on a post-consolidation basis) to convert to ordinary shares, in accordance with shareholder approval received at the AGM on 16 November 2018.

 


    6a   

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

 

If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

      Yes
        
 
    6b    The date the security holder resolution under rule 7.1A was passed       1 November 2019
        
 
    6c    Number of +securities issued without security holder approval under rule 7.1       Nil
        
 
    6d    Number of +securities issued with security holder approval under rule 7.1A       Nil
        
 
    6e    Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)      

1.  3,600,000 performance rights approved at the AGM on 1 November 2019 for CEO & Executive Director, Mr Marc Voigt.

 

2.  1,500,000 performance rights approved at the AGM on 1 November 2019 for Non-Executive Director, Mr Pete Meyers.

 

4.  250,000 ordinary shares are issued on exercise of 2nd tranche of performance rights approved for Non-Executive Director, Dr Russell Howard at the AGM on 16 November 2018.

 

        
 
    6f    Number of +securities issued under an exception in rule 7.2      

3.  833,334 ordinary shares are issued on exercising performance rights

 

        
 
    6g    If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.       Not applicable

 

+ See chapter 19 for defined terms.          
Appendix 3B Page 4       04/03/2013


 
    6h    If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements           Not applicable
        
    6i    Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements           Refer to Annexure 1
       
    7   

+Issue dates

 

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

 

Cross reference: item 33 of Appendix 3B.

     2 December 2019
       
             

Number

  

+Class

    8

   Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)      388,797,604    Fully paid ordinary shares

 

                 Number   

+Class - Options

             

Amount

  

Exercise Price

  

Expiration Date

    9    Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)           37,144,524    $0.235    4 August 2020
        79,311    $0.568    30 October 2020
        102,628    $0.398    7 March 2021
        847,600    $0.248    4 August 2025


              Number   

+Class – Warrants over NASDAQ listed American Depository Shares

             

Amount

  

Exercise Price

  

Terms

    

       

1,553,718

   US$         2.49    Each Warrant entitles the holder to purchase 1 ADS (where one ADS = 10 Ordinary Shares) at the exercise price and is exercisable immediately. Each Warrant will expire on 5 January 2023.
       

2,080,000

   US$         2.49    Each Warrant entitles the holder to purchase 1 ADS (where one ADS = 10 Ordinary Shares) at the exercise price and is exercisable immediately. Each Warrant will expire on 12 February 2022.
              Number   

+Class – Performance Rights

             

Amount

  

Type

  

Expiration Date

       

273,637

   NED PRs    Each tranche of NED PRs will expire one year after Vesting Date if not exercised as indicated in the appendix 3B released on 6 December 2016.
       

426,654

   NED PRs    Each tranche of NED PRs will expire one year after Vesting Date if not exercised as indicated in the appendix 3B released on 4 December 2016.
       

2,833,334

   LTI    Each tranche of LTIs will expire one year after Vesting Date if not exercised as indicated in the appendix 3B released on 4 December 2017.
       

500,000

   LTI    LTIs will vest on 1 October 2020.
       

387,560

   LTI    Each tranche of LTIs will expire one year after Vesting Date if not exercised as indicated in the appendix 3B released on 2 October 2018.

    

       

500,000

   NED PRs    Each tranche of NED PRs will expire one year after Vesting Date if not exercised as indicated in the appendix 3B released on 21 November 2018.

 

+ See chapter 19 for defined terms.          
Appendix 3B Page 6       04/03/2013


       

4,500,000

   LTI    Each tranche of LTIs will expire one year after the relevant vesting date unless exercised as indicated in the appendix 3B released on 3 October 2019, subject to accelerated vesting conditions.
       

1,500,000

   NED PRs    Each tranche of NED PRs will expire one year after Vesting Date if not exercised subject to accelerated vesting conditions.
       

3,600,000

   LTI    Each tranche of LTIs will expire one year after the relevant vesting date unless exercised, subject to accelerated vesting conditions.
              Number   

+Class – Convertible Notes

             

Amount

  

Type

  

Expiration Date

       

13,750,828

  

Convertible Notes each with a face value of AU$1, expiring on 4 August 2025.

 

             
    10    Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)      Unchanged

Part 2 - Bonus issue or Pro rata issue

 

    11    Is security holder approval required?           Not applicable
          
    12    Is the issue renounceable or non-renounceable?      Not applicable
          
    13    Ratio in which the +securities will be offered      Not applicable
          
    14    +Class of +securities to which the offer relates      Not applicable
          
    15    +Record date to determine entitlements      Not applicable
          
    16    Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?          Not applicable                    


    17    Policy for deciding entitlements in relation to fractions      Not applicable
          
    18   

Names of countries in which the entity has security holders who will not be sent new offer documents

 

Note: Security holders must be told how their entitlements are to be dealt with.

 

Cross reference: rule 7.7.

     Not applicable
          
    19    Closing date for receipt of acceptances or renunciations      Not applicable
          
    20    Names of any underwriters      Not applicable
          
    21    Amount of any underwriting fee or commission      Not applicable
          
    22    Names of any brokers to the issue      Not applicable
          
    23    Fee or commission payable to the broker to the issue      Not applicable
          
    24    Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders      Not applicable
          
    25    If the issue is contingent on security holders’ approval, the date of the meeting      Not applicable
          
    26    Date entitlement and acceptance form and offer documents will be sent to persons entitled      Not applicable
          
    27    If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders      Not applicable
          
    28    Date rights trading will begin (if applicable)      Not applicable
          
    29    Date rights trading will end (if applicable)     

Not applicable

          
    30    How do security holders sell their entitlements in full through a broker?      Not applicable

 

+ See chapter 19 for defined terms.          
Appendix 3B Page 8       04/03/2013


    31    How do security holders sell part of their entitlements through a broker and accept for the balance?     

Not applicable

 

 

       
    32    How do security holders dispose of their entitlements (except by sale through a broker)?     

Not applicable

 

       
    33    +Issue date     

Not applicable

 


Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

 

    34

  

Type of +securities

(tick one)

    (a)

      +Securities described in Part 1
    (b)      

All other +securities

 

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

 

Tick to indicate you are providing the information or documents

 

    35       If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
    36      

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

 

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

    37       A copy of any trust deed for the additional +securities

 

+ See chapter 19 for defined terms.          
Appendix 3B Page 10       04/03/2013


Entities that have ticked box 34(b)

 

    38    Number of +securities for which +quotation is sought      

N/A

 

           
    39    +Class of +securities for which quotation is sought      

N/A

 

           
    40   

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

 

If the additional +securities do not rank equally, please state:

 

•   the date from which they do

 

•   the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

 

•   the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

      N/A
           
    41   

Reason for request for quotation now

 

Example: In the case of restricted securities, end of restriction period

 

(if issued upon conversion of another +security, clearly identify that other +security)

      N/A
           
              

Number

  

+Class

    42    Number and +class of all +securities quoted on ASX (including the +securities in clause 38)      

N/A

 

 

   N/A


Quotation agreement

 

1

+Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

 

2

We warrant the following to ASX.

 

   

The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

 

   

There is no reason why those +securities should not be granted +quotation.

 

   

An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

 

   

Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

 

   

If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

 

3

We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

 

4

We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

 

Sign here:   LOGO    Date: 2 December 2019
  (Director/Company secretary)   
Print name: Tom Bloomfield   

== == == == ==

 

+ See chapter 19 for defined terms.          
Appendix 3B Page 12       04/03/2013


Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

 

Rule 7.1 – Issues exceeding 15% of capital
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue    308,443,162

Add the following:

 

•   Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2

 

•   Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval

 

•   Number of partly paid +ordinary securities that became fully paid in that 12 month period

 

Note:

 

•   Include only ordinary securities here – other classes of equity securities cannot be added

 

•   Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

 

•   It may be useful to set out issues of securities on different dates as separate line items

   80,352,402
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period   

Nil

“A”    388,795,564

 

+ See chapter 19 for defined terms.          
04/03/2013       Appendix 3B Page 13


Step 2: Calculate 15% of “A”
“B”   

0.15

 

[Note: this value cannot be changed]

Multiply “A” by 0.15    58,319,334
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used

Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:

 

•   Under an exception in rule 7.2

 

•   Under rule 7.1A

 

•   With security holder approval under rule 7.1 or rule 7.4

 

Note:

 

•   This applies to equity securities, unless specifically excluded – not just ordinary securities

 

•   Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

 

•   It may be useful to set out issues of securities on different dates as separate line items

  

 

Nil

“C”

  

Nil

Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1

“A” x 0.15

 

Note: number must be same as shown in Step 2

   58,319,334

Subtract “C”

 

Note: number must be same as shown in Step 3

   Nil
Total [“A” x 0.15] – “C”   

58,319,334

 

[Note: this is the remaining placement capacity under rule 7.1]

 

+ See chapter 19 for defined terms.          
Appendix 3B Page 14       04/03/2013


Part 2

 

Rule 7.1A – Additional placement capacity for eligible entities
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

“A”

 

Note: number must be same as shown in Step 1 of Part 1

   388,795,564
Step 2: Calculate 10% of “A”
“D”   

0.10

 

Note: this value cannot be changed

Multiply “A” by 0.10    38,879,556
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used

Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

 

Notes:

 

•   This applies to equity securities – not just ordinary securities

 

•   Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed

 

•   Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

 

•   It may be useful to set out issues of securities on different dates as separate line items

  

Nil

“E”    Nil

 

+ See chapter 19 for defined terms.          
04/03/2013       Appendix 3B Page 15


Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

“A” x 0.10

 

Note: number must be same as shown in Step 2

   38,879,556

Subtract “E”

 

Note: number must be same as shown in Step 3

  

Nil

Total [“A” x 0.10] – “E”

  

38,879,556

 

Note: this is the remaining placement capacity under rule 7.1A

 

+ See chapter 19 for defined terms.          
Appendix 3B Page 16       04/03/2013